The sustained success and dominant position of Eylea in the anti-VEGF segment are fundamentally underpinned by extensive and rigorous Eylea Market research, which has continuously generated robust clinical data that inform treatment standards and bolster physician confidence. This research spans a vast portfolio of Phase III clinical trials, such as the VISTA and VIVID studies for DME and the VIEW studies for wAMD, which not only demonstrated the drug’s superior efficacy in improving best-corrected visual acuity but also established its favorable safety profile. Crucially, the research agenda has consistently evolved to address real-world clinical practice needs, moving beyond fixed dosing schedules to explore flexible dosing regimens like 'pro re nata' (PRN) and, most notably, 'treat-and-extend' (T&E). The T&E protocol, which allows for the progressive lengthening of the interval between injections based on individual patient response, has become the dominant treatment strategy, dramatically reducing the burden of frequent clinic visits for patients while maintaining excellent visual results. This patient-centric data has been instrumental in distinguishing Eylea from its competitors, including off-label alternatives.

Moreover, the most recent and significant wave of Eylea Market research is focused on the high-dose Eylea HD (aflibercept 8 mg), which has been rigorously tested in the PULSAR and PHOTON trials. These pivotal studies provided the clinical validation necessary for regulatory approval, proving that the 8 mg dose can deliver non-inferior visual outcomes to the standard 2 mg dose but with significantly extended treatment intervals of up to 16 weeks or even longer. This data is the lynchpin of the brand’s strategy against incoming biosimilars, as it establishes a compelling clinical and convenience advantage that is difficult for a biosimilar of the 2 mg dose to match. The continuous stream of real-world evidence from observational studies and registries further supports the clinical trial findings, providing valuable insights into effectiveness and safety across diverse and complex patient populations outside of controlled trial settings. This cycle of continuous research—from efficacy to flexible dosing to high-dose development—is a non-negotiable requirement for market leadership, as it provides the scientific and commercial justification for Eylea’s continued dominance and premium pricing in a rapidly evolving therapeutic area. For a comprehensive look at the market, see this Eylea Market research